Novus Therapeutics is a pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat. Co. has two platform technologies, a surfactant and a foam. Co.'s primary program, OP0201, is a surfactant-based nasal aerosol drug-device combination product candidate being developed as a treatment option for patients at risk for, or with, otitis media (OM). OM is defined as middle ear inflammation and effusion with or without infection. Co. also has a foam-based drug delivery technology platform, which may be developed to deliver drugs into the ear, nasal, and sinus cavities.